Numerate, Inc., a San Bruno, CA-based biotechnology company, completed an $8m financing.
The round was co-led by Atlas Venture and Lilly Ventures, with participation from existing investors. In conjunction with the funding, Bruce Booth, Ph.D, Partner at Atlas Venture, and Steve Hall, Ph.D., Venture Partner at Lilly Ventures, joined Numerate’s Board of Directors.
The company intends to use the funds to advance its lead programs.
Led by Guido Lanza, president and chief executive officer, Numerate has developed a drug design platform that uses all relevant data (SAR, patents, phenotypic data, etc.) to treat cardiovascular, metabolic and neurodegenerative diseases.
In metabolic disease, the company is targeting the free fatty acid receptors to address diabetes, obesity and related co-morbidities, while in cardiovascular disease they are targeting the Ryanodine receptor 2 to discover improved drugs for heart failure and arrhythmia.
FinSMEs
24/06/2014